Flex Pharma, Inc. (FLKS) Files Form 4 Insider Buying : Christoph H Westphal Buys 2,700 Shares

Flex Pharma, Inc. (FLKS): Christoph H Westphal , CEO of Flex Pharma, Inc. purchased 2,700 shares on Jun 23, 2016. The Insider buying transaction was reported by the company on Jun 24, 2016 to the Securities and Exchange Commission. The shares were purchased at $11.28 per share for a total value of $30,456.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 22, 2016, Christoph H Westphal (CEO) purchased 5,700 shares at $11.05 per share price.On Mar 16, 2016, Michelle Stacy (director) purchased 2,585 shares at $9.63 per share price.Also, On Mar 15, 2016, Fund Ii, L.p. Longwood (10% owner) purchased 89,680 shares at $7.00 per share price.On Mar 15, 2016, Thomas Wessel (Chief Medical Officer) purchased 20,000 shares at $8.14 per share price.

Shares of Flex Pharma Inc (FLKS) ended Friday, Jun 24, 2016 session in red amid volatile trading. The shares closed down -0.5 points or -4.42% at $10.8 with 6,06,533 shares getting traded. Post opening the session at $10.51, the shares hit an intraday low of $10.264 and an intraday high of $11.06 and the price vacillated in this range throughout the day. The company has a market cap of $194 M and the number of outstanding shares has been calculated to be 1,79,67,891 shares. The 52-week high of Flex Pharma Inc is $20.48 and the 52-week low is $6.48.

Flex Pharma Inc Money Flow Index Chart

Flex Pharma Inc. is a biotechnology company that is developing treatments for exercise-associated muscle cramps nocturnal leg cramps and spasms for neuromuscular conditions. The Company focuses its drug development efforts on developing a product to treat nocturnal leg cramps. The Company’s treatment which forms the basis of both drug product and consumer product development efforts activates the transient receptor potential (TRP) cation channel receptors in primary sensory neurons in the spinal cord that enhances overall inhibitory tone in motor neurons throughout the body. The Company’s pre-clinical drug product candidates are offered for Nocturnal leg cramps and MS spasticity cervical dystonia and/or SCI spasticity. The Company’s consumer brand and products focuses athletes experiencing exercise-associated muscle cramps or EAMCs. The Company has commenced formulation and commercialization efforts of its consumer brand.

Leave a Reply

Flex Pharma Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Flex Pharma Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.